#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention

Episode 384

0:00-52:40

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this special episode, Peter takes a deep dive into obicetrapib, an investigational drug that has captured his attention and renewed interest in an entire class of therapies known as CETP inhibitors. He explains what obicetrapib is and how it works, revisits the history of CETP inhibitors and why earlier versions of these drugs failed—sometimes dramatically—and breaks down the key clinical trials designed to evaluate their impact on cardiovascular risk. Peter examines how obicetrapib influences major lipid biomarkers, including LDL cholesterol and lipoprotein(a) [Lp(a)], and discusses emerging evidence from a study that explored the drug's effects on Alzheimer's-related blood biomarkers. He also highlights intriguing findings in individuals carrying the APOE4 allele and reflects on what these early results may mean for both cardiovascular disease prevention and potential implications for Alzheimer's risk, as well as how he is thinking about this therapy in the context of caring for his own patients.

Publisher

The Peter Attia Drive

Link

peterattiamd.com/obicetrapib/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260316-pod-obicetrapib&utm_content=260316-pod-obicetrapib-podfeed

Published

March 16, 2026

Duration

53 min

Format

Podcast

Category

Lifestyle · Health & Wellness

Source

RSS feed

Host

Peter Attia, MD

TP

The Peter Attia Drive

@peterattiadrive

#cetpinhibitor #cardiovascularbenefits #potentialalzheimersprevention

The Nile